JP2010539959A5 - - Google Patents

Download PDF

Info

Publication number
JP2010539959A5
JP2010539959A5 JP2010527323A JP2010527323A JP2010539959A5 JP 2010539959 A5 JP2010539959 A5 JP 2010539959A5 JP 2010527323 A JP2010527323 A JP 2010527323A JP 2010527323 A JP2010527323 A JP 2010527323A JP 2010539959 A5 JP2010539959 A5 JP 2010539959A5
Authority
JP
Japan
Prior art keywords
mir
hsa
oligomer
complementary
nucleobase sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010527323A
Other languages
English (en)
Other versions
JP2010539959A (ja
JP6035010B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2008/000344 external-priority patent/WO2009043353A2/en
Publication of JP2010539959A publication Critical patent/JP2010539959A/ja
Publication of JP2010539959A5 publication Critical patent/JP2010539959A5/ja
Application granted granted Critical
Publication of JP6035010B2 publication Critical patent/JP6035010B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (50)

  1. 7 - 10 核酸塩基の連続核酸塩基配列を含む7 - 10核酸塩基の長さのオリゴマーであって、オリゴマーの核酸塩基単位の少なくとも70%がロックト核酸(LNA) 核酸塩基単位であり、オリゴマーが少なくとも一つのホスホロチオエート結合を含む、オリゴマー。
  2. 連続核酸塩基配列の核酸塩基単位の間に存在するヌクレオシド間結合の少なくとも75%がホスホロチオエートヌクレオシド間結合である請求項 1のオリゴマー。
  3. 連続核酸塩基配列の核酸塩基単位の間に存在するすべてのヌクレオシド間結合がホスホロチオエートヌクレオシド間結合である請求項 1のオリゴマー。
  4. ３’ 末端 ＬＮＡ 単位および５’ 末端 LNA 単位を含む請求項1 - 3のいずれかのオリゴマー。
  5. 連続核酸塩基配列の核酸塩基単位のすべてがLNA 核酸塩基単位である請求項1 - 4のいずれかのオリゴマー。
  6. オリゴマーが連続核酸塩基配列からなる請求項1 - 5のいずれかのオリゴマー。
  7. 連続核酸塩基配列が、哺乳動物、ヒトまたはウイルスのマイクロRNA配列のシード配列に相補的な配列を含む請求項1 - 6のいずれかのオリゴマー。
  8. 連続核酸塩基配列が以下からなる群から選択されるmiRNAに存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー: ebv-miR-BHRF1-2、hsa-miR-140、ebv-miR-BART15、ebv-miR-BART8-5p、ebv-miR-BART11-5p、hsa-miR-561、hsa-miR-511、hsa-miR-511、hsa-miR-501、hsa-miR-204、hsa-miR-211、hsa-miR-579、hsa-miR-609、hsa-miR-567、hsa-miR-409-3p、hsa-miR-584、kshv-miR-K12-6-3p、hsa-miR-657、hsa-miR-451、hsa-miR-223、hsa-miR-145、hsa-miR-582、hsa-miR-137、hsa-miR-218、hsa-miR-218、hsa-miR-520f、hsa-miR-135a、hsa-miR-135a、hsa-miR-135b、hsa-miR-532、hsa-miR-188、hsa-miR-422b、hsa-miR-422a、hcmv-miR-US25-2-3p、ebv-miR-BART9、ebv-miR-BART13、hsa-miR-376a*、hsa-miR-586、hsa-miR-136、hsa-miR-660、hsa-miR-23a、hsa-miR-23b、ebv-miR-BART19、hsa-miR-453、hsa-miR-382、hsa-miR-578、hsa-miR-581、hsa-miR-142-3p、hsa-miR-122a、hsa-miR-199a、hsa-miR-199a、hsa-miR-199b、hsa-miR-10a、hsa-miR-10b、hsa-miR-649、hsa-miR-190、hsa-miR-1、hsa-miR-206、hsa-miR-1、hsa-miR-613、hsa-miR-9、hsa-miR-9、hsa-miR-9、hsa-miR-509、hsa-miR-522、hsa-miR-423、hsa-miR-553、hsa-miR-210、hsa-miR-662、hsa-miR-196a、hsa-miR-196a、hsa-miR-196b、ebv-miR-BART3-5p、hsa-miR-633、hsa-miR-30a-3p、hsa-miR-30e-3p、hsa-miR-17-3p、hsa-miR-34b、hsa-miR-575、hsa-miR-139、hsa-miR-27a、hsa-miR-27b、hsa-miR-142-5p、ebv-miR-BART2、hsa-miR-630、hsa-miR-187、hsa-miR-626、hcmv-miR-US25-2-5p、hsa-miR-627、hsa-miR-642、hsa-miR-93、hsa-miR-302a、hsa-miR-302b、hsa-miR-302c、hsa-miR-302d、hsa-miR-372、hsa-miR-373、hsa-miR-520e、hsa-miR-520a、hsa-miR-526b*、hsa-miR-520b、hsa-miR-520c、hsa-miR-520d、hsa-miR-155、kshv-miR-K12-11、ebv-miR-BART14-3p、hsa-miR-565、hsa-miR-645、hsa-miR-191*、hsa-miR-523、hsa-miR-518f、hsa-miR-518e、hsa-miR-518a、hsa-miR-518a、hsa-miR-556、hsa-miR-28、hsa-miR-646、kshv-miR-K12-9*、hsa-miR-516-3p、hsa-miR-516-3p、hsa-miR-516-3p、hsa-miR-516-3p、hsa-miR-483、hsa-miR-515-3p、hsa-miR-515-3p、hsa-miR-566、hsa-miR-614、hsa-miR-18a*、hsa-miR-328、hsa-miR-769-5p、hsa-miR-500、hsa-miR-606、hsa-miR-345、hsa-miR-151、hsa-miR-499、hsa-miR-521、hsa-miR-521、hsa-miR-603、hsa-miR-146a、hsa-miR-146b、hsa-miR-549、hsa-miR-154、hsa-miR-21、hsa-miR-590、hsa-miR-656、hsa-miR-643、kshv-miR-K12-9、hsa-miR-202、hsa-miR-144、hsa-miR-202*、hsa-miR-448、ebv-miR-BART4、hsa-miR-433、hsa-miR-542-5p、hsa-miR-651、hsa-miR-620、hsa-miR-31、hsa-miR-205、hsa-miR-598、hsa-miR-517b、hsa-miR-217、hsa-miR-103、hsa-miR-103、hsa-miR-107、hsa-miR-338、hsa-miR-767-5p、hsa-miR-493-5p、hsa-miR-221、hsa-miR-222、hsa-miR-489、hsa-miR-641、hsa-miR-302c*、hsa-miR-494、hsa-miR-380-3p、hsa-miR-576、hsa-miR-580、hsa-miR-186、ebv-miR-BART8-3p、hsa-miR-539、hsa-miR-607、kshv-miR-K12-10b、kshv-miR-K12-10a、hsa-miR-636、hsa-miR-362、hsa-miR-623、hsa-miR-33、hsa-miR-33b、hsa-miR-595、hsa-miR-138、hsa-miR-138、hsa-miR-552、hsa-miR-302a*、ebv-miR-BART1-5p、ebv-miR-BART16、hsa-miR-34a、hsa-miR-34c、hsa-miR-449、hsa-miR-449b、hsa-miR-128a、hsa-miR-128b、hsa-miR-573、hsa-miR-520g、hsa-miR-520h、ebv-miR-BHRF1-2*、hsa-miR-622、hsa-miR-594、hsa-miR-512-3p、hsa-miR-512-3p、hsa-miR-370、hsa-miR-485-5p、hsa-miR-320、hsa-miR-504、hsa-miR-492、hsa-miR-200b、hsa-miR-200c、hsa-miR-429、hsa-miR-134、hsa-miR-141、hsa-miR-200a、hsa-miR-548a、hsa-miR-548a、hsa-miR-548a、hsa-miR-591、hsa-miR-496、hsa-miR-569、hsa-miR-768-3p、hsa-miR-203、hsa-miR-571、hsa-miR-147、ebv-miR-BART12、hsa-miR-608、hsa-miR-331、hsa-miR-631、hsa-miR-490、hsa-miR-432*、hcmv-miR-UL70-3p、hcmv-miR-US4、hsa-miR-299-3p、hsa-miR-326、hsa-miR-661、hsa-miR-637、hsa-miR-663、hsa-miR-602、hsa-miR-564、hsa-miR-95、hsa-miR-768-5p、hsa-miR-658、hsa-miR-583、hsa-miR-510、ebv-miR-BART20-5p、hsa-miR-214、kshv-miR-K12-1、hsa-miR-513、hsa-miR-513、ebv-miR-BART20-3p、hsa-miR-375、ebv-miR-BART18、hsa-miR-638、hsa-miR-450、hsa-miR-450、hsa-miR-604、kshv-miR-K12-8、hsa-miR-503、hsa-miR-126、ebv-miR-BART1-3p、hsa-miR-220、hcmv-miR-UL112、hsa-miR-208、kshv-miR-K12-2、hsa-let-7a、hsa-let-7a、hsa-let-7a、hsa-let-7b、hsa-let-7c、hsa-let-7d、hsa-let-7e、hsa-let-7f、hsa-let-7f、hsa-miR-98、hsa-let-7g、hsa-let-7i、hsa-miR-325、hsa-miR-199a*、hsa-miR-199a*、hsa-miR-601、hsa-miR-384、ebv-miR-BART7、hsa-miR-153、hsa-miR-153、hsa-miR-526b、hsa-miR-125b、hsa-miR-125a、hsa-miR-125b、hsa-miR-432、hsa-miR-765、hsa-miR-526c、hsa-miR-526c、hsa-miR-526c、hsa-miR-518f*、hsa-miR-526a、hsa-miR-526a、hsa-miR-526a、hsa-miR-526c、hsa-miR-526a、hsa-miR-526c、hsa-miR-526c、hsa-miR-368、hsa-miR-520a*、hsa-miR-525、hsa-miR-24、hsa-miR-24、hsa-miR-600、hsa-miR-542-3p、hsa-miR-194、hsa-miR-194、hsa-miR-421、hsa-miR-570、hsa-miR-555、hsa-miR-381、hsa-miR-527、hsa-miR-527、hsa-miR-527、hsa-miR-524*、hsa-miR-659、kshv-miR-K12-3、hsa-miR-219、hsa-miR-219、hsa-miR-599、hsa-miR-339、ebv-miR-BART6-5p、kshv-miR-K12-3*、hsa-miR-493-3p、hsa-miR-212、hsa-miR-132、hcmv-miR-UL70-5p、hsa-miR-340、hsa-miR-452*、hsa-miR-801、hsa-miR-149、hsa-miR-484、hsa-miR-572、hcmv-miR-US25-1、hsa-miR-337、hcmv-miR-UL148D、hsa-miR-668、hsa-miR-454-5p、hsa-miR-769-3p、ebv-miR-BART6-3p、hsa-miR-548c、hsa-miR-129、hsa-miR-129、hsa-miR-431、hsa-miR-502、hcmv-miR-US33、hsa-miR-648、hsa-miR-18a、hsa-miR-18b、hsa-miR-17-5p、hsa-miR-20a、hsa-miR-106a、hsa-miR-106b、hsa-miR-20b、hsa-miR-519d、hsa-miR-632、hsa-miR-647、hsa-miR-639、hsa-miR-558、hsa-miR-596、ebv-miR-BART17-3p、kshv-miR-K12-5、hsa-miR-105、hsa-miR-105、hsa-miR-644、hsa-miR-635、hsa-miR-654、hsa-miR-560、hsa-miR-652、hsa-miR-525*、hsa-miR-524、hsa-miR-518b、hsa-miR-518c、hsa-miR-518d、hsa-miR-562、hcmv-miR-UL22A、hsa-miR-335、hsa-miR-512-5p、hsa-miR-512-5p、kshv-miR-K12-6-5p、hsa-miR-766、hsa-miR-498、hcmv-miR-US5-1、hsa-miR-617、hsa-miR-554、hsa-miR-127、hsa-miR-455、hsa-miR-519e、hsa-miR-346、hsa-miR-22、hsa-miR-324-3p、hsa-miR-193a、hsa-miR-193b、kshv-miR-K12-12、hsa-miR-371、hsa-miR-615、hsa-miR-671、hsa-miR-133a、hsa-miR-133a、hsa-miR-133b、hsa-miR-629、hsa-miR-324-5p、hsa-miR-605、hsa-miR-365、hsa-miR-365、hsa-miR-296、hsa-miR-409-5p、hsa-miR-412、hsa-miR-329、hsa-miR-329、ebv-miR-BART10、hsa-miR-548b、hsa-miR-548d、hsa-miR-548d、hsa-miR-299-5p、hsa-miR-550、hsa-miR-550、hsa-miR-200a*、hsa-miR-486、hsa-miR-487b、hsa-miR-770-5p、hsa-miR-101、hsa-miR-101、hsa-miR-189、ebv-miR-BART14-5p、hsa-miR-154*、hsa-miR-487a、hsa-miR-369-3p、kshv-miR-K12-4-3p、hsa-miR-380-5p、hsa-miR-563、hsa-miR-758、hsa-miR-378、hsa-miR-611、ebv-miR-BART17-5p、hsa-miR-369-5p、hsa-miR-379、hsa-miR-411、hsa-miR-7、hsa-miR-7、hsa-miR-7、hsa-miR-597、hsa-miR-224、hsa-miR-507、hsa-miR-557、hsa-miR-25、hsa-miR-32、hsa-miR-92、hsa-miR-92、hsa-miR-363、hsa-miR-367、hsa-miR-92b、hsa-miR-96、hsa-miR-183、hsa-miR-506、hsa-miR-588、hsa-miR-197、ebv-miR-BART3-3p、hsa-miR-514、hsa-miR-514、hsa-miR-514、hsa-miR-425-5p、hsa-miR-342、ebv-miR-BART11-3p、hsa-miR-505、hsa-miR-302b*、hsa-miR-410、kshv-miR-K12-4-5p、hsa-miR-495、hsa-miR-126*、hsa-miR-323、hsa-miR-508、hsa-miR-585、hsa-miR-99a、hsa-miR-100、hsa-miR-99b、hsa-miR-26a、hsa-miR-26b、hsa-miR-26a、hsa-miR-182*、hsa-miR-618、hsa-miR-9*、hsa-miR-9*、hsa-miR-9*、hsa-miR-192、hsa-miR-215、hcmv-miR-US5-2、hsa-miR-488、hsa-miR-587、hsa-miR-374、ebv-miR-BART5、ebv-miR-BHRF1-1、hsa-miR-143、hsa-miR-363*,hsa-miR-518c*、hsa-miR-516-5p、hsa-miR-516-5p、hsa-miR-619、hsa-miR-491、ebv-miR-BHRF1-3、hsa-miR-184、hsv1-miR-H1、hsa-miR-181a*、hsa-miR-517*、hsa-miR-517*、hsa-miR-517*、hsa-miR-376a、hsa-miR-376b、hsa-miR-376a、hsa-miR-185、hsa-miR-361、hsa-miR-383、hsa-miR-198、hcmv-miR-UL22A*、hsa-miR-181a、hsa-miR-181b、hsa-miR-181c、hsa-miR-181a、hsa-miR-181b、hsa-miR-181d、hsa-miR-592、hsa-miR-216、hsa-miR-767-3p、hsa-miR-574、hsa-miR-452、hsa-miR-517a、hsa-miR-517c、hsa-miR-148a、hsa-miR-152、hsa-miR-148b、hsa-miR-519c、hsa-miR-519b、hsa-miR-519a、hsa-miR-519a、hsa-miR-544、hsa-miR-612、hsa-miR-650、hsa-miR-124a、hsa-miR-124a、hsa-miR-124a、hsa-miR-621、hsa-miR-15a、hsa-miR-16、hsa-miR-16、hsa-miR-15b、hsa-miR-195、hsa-miR-424、hsa-miR-497、hsa-miR-634、hsa-miR-330、hsa-miR-640、kshv-miR-K12-7、hsa-miR-551a、hsa-miR-551b、hsa-miR-624、hsa-miR-593、hsa-miR-29a、hsa-miR-29b、hsa-miR-29b、hsa-miR-29c、hsa-miR-485-3p、hsa-miR-655、hsa-miR-377、hsa-miR-802、hsa-miR-589、hsa-miR-30a-5p、hsa-miR-30c、hsa-miR-30d、hsa-miR-30b、hsa-miR-30c、hsa-miR-30e-5p、hsa-miR-653、hsa-miR-628、hsa-miR-559、hsa-miR-610、hsa-miR-568、hcmv-miR-UL36、hsa-miR-625、hsa-miR-425-3p、hsa-miR-191、hsa-miR-130a、hsa-miR-301、hsa-miR-130b、hsa-miR-454-3p、hsa-miR-182、hsa-miR-545、hsa-miR-515-5p、hsa-miR-519e*、hsa-miR-515-5p、hsa-miR-150、hsa-miR-577、hsa-miR-19a、hsa-miR-19b、hsa-miR-19b、hsa-miR-520d*、hsa-miR-373*、およびhsa-miR-616。
  9. 連続核酸塩基配列が以下からなる群から選択されるmiRNAに存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー：miR-1、miR-10b、miR-17-3p、miR-18、miR-19a、miR-19b、miR-20、miR-21、miR-34a、miR-93、miR-106a、miR-106b、miR-122、miR-133、miR-134、miR-138、miR-155、miR-192、miR-194、miR-221、miR-222、およびmiR-375。
  10. 連続核酸塩基配列がhsa-miR-33またはhsa-miR-33bに存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  11. 連続核酸塩基配列がhsa-miR-9またはhsa-miR-9*に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  12. 連続核酸塩基配列がhsa-miR-10aまたはhsa-miR-10bに存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  13. 連続核酸塩基配列がhsa-miR-20aまたはhsa-miR-20bに存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  14. 連続核酸塩基配列がhsa-miR-19aまたはhsa-miR-19bに存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  15. 連続核酸塩基配列がhsa-miR-106aに存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  16. 連続核酸塩基配列がhsa-miR-155に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  17. 連続核酸塩基配列がhsa-miR-21に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  18. 連続核酸塩基配列がhsa-miR-122aに存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  19. 連続核酸塩基配列がhsa-miR-208に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  20. 連続核酸塩基配列がhsa-miR-499に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  21. 連続核酸塩基配列がhsa-miR-15に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  22. 連続核酸塩基配列がhsa-miR-195に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  23. 連続核酸塩基配列がhsa-miR-451に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  24. 連続核酸塩基配列がhsa-miR-29に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  25. 連続核酸塩基配列がhsa-miR-92に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  26. 連続核酸塩基配列がhsa-miR-143に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  27. 連続核酸塩基配列がhsa-miR-145に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  28. 連続核酸塩基配列がhsa-miR-199に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  29. 連続核酸塩基配列がhsa-miR-206に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  30. 連続核酸塩基配列がhsa-miR-378に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  31. 連続核酸塩基配列がhsa-miR-375に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  32. 連続核酸塩基配列がhsa-miR-138に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  33. 連続核酸塩基配列がhsa-miR-34aに存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  34. 連続核酸塩基配列がhsa-miR-27aに存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  35. 連続核酸塩基配列がhsa-miR-182に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  36. 連続核酸塩基配列がhsa-miR-183に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  37. 連続核酸塩基配列がhsa-miR-96に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  38. 連続核酸塩基配列がhsa-miR-338に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  39. 連続核酸塩基配列がhsa-miR-30に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  40. 連続核酸塩基配列がhsa-miR-133に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  41. 連続核酸塩基配列がhsa-miR-17に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  42. 連続核酸塩基配列がhsa-miR-24に存在する対応するヌクレオチド配列に相補的である請求項1-7のいずれかのオリゴマー。
  43. 連続核酸塩基配列が以下からなる群から選択される配列からなるかまたはかかる配列を含む請求項1-7のいずれかのオリゴマー: AAAAGAT、AAACCAC、AAACCGT、AAACTGT、AAACTTT、AAAGACA、AAAGGAT、AAAGGGA、AAATGAA、AACACCC、AACATAC、AACATTC、AACCATA、AACCATC、AACCTGC、AACGGTT、AACTGAC、AACTGGA、AACTGTA、AAGCAAT、AAGCACA、AAGCACT、AAGCCAT、AAGGCAT、AAGGGAT、AAGTCCA、AAGTGGA、AAGTGTT、AAGTTAC、AATCTAC、AATGCAT、AATGGAG、AATGGGT、AATGTGA、ACAAAAC、ACAACCT、ACAACTT、ACAAGAA、ACACAAG、ACACTAC、ACACTCC、ACACTGG、ACAGGGT、ACAGGTT、ACATATC、ACATTCC、ACCAAAG、ACCAATC、ACCATTT、ACCGAGC、ACCGTTT、ACGCAC、ACGTGGG、ACTACCT、ACTAGGT、ACTATTA、ACTGAAA、ACTGCAG、ACTGCCT、ACTGGCT、ACTGTAG、ACTGTGA、ACTTTAT、AGAAAAT、AGAATAC、AGACACG、AGACAGC、AGACCGC、AGACTCA、AGAGGGA、AGCACTT、AGCATTA、AGCATTT、AGCCAGC、AGCCTAG、AGCGCAG、AGCGCGT、AGCGCTT、AGCTCAT、AGCTCCT、AGCTGCT、AGCTGGG、AGGAAGC、AGGAGTG、AGGCACT、AGGCGCC、AGGCGTT、AGGGCAG、AGGGCCA、AGGTCTC、AGGTGCA、AGTAGTT、AGTCAGC、AGTCTAG、AGTCTTA、AGTGCGT、AGTGTGT、AGTTCTC、AGTTGTC、ATAACCT、ATAAGCT、ATAATAT、ATACAAG、ATACCCA、ATACCTC、ATACTGT、ATAGGAA、ATATGCA、ATCAGGT、ATCATGA、ATCCCCG、ATCCTAA、ATCTCCA、ATCTTGC、ATGAAGG、ATGACGT、ATGCACG、ATGCAGT、ATGCTGC、ATGCTGG、ATGGTGC、ATGTACA、ATGTAGC、ATGTCAC、ATGTCTT、ATGTTAA、ATGTTTC、ATTACAT、ATTAGAA、ATTCTCA、ATTCTTT、ATTGTGA、ATTTCTC、ATTTGAA、CAACACC、CAACACT、CAAGCAC、CAAGGAT、CAAGGGA、CAATGCA、CACACTT、CACCAGC、CACCTGT、CACGTTT、CACTAAG、CACTCTA、CACTGCC、CACTGTG、CACTTCA、CACTTTG、CAGAATT、CAGACTG、CAGATGG、CAGCACT、CAGCAGG、CAGCCTC、CAGCTTT、CAGGGTC、CAGGTCC、CAGTATT、CAGTCAC、CAGTGTT、CAGTTTT、CATGGTC、CATGTAA、CATTAAC、CATTGTG、CATTTCA、CCAACTC、CCACACA、CCACAGG、CCACCCC、CCAGGGG、CCAGGTC、CCAGGTT、CCATCCA、CCATCCC、CCATGTC、CCCACAT、CCCAGAG、CCCAGGC、CCCCCAG、CCCCGCC、CCCGTGT、CCGTGCC、CCGTTGA、CCTCCAA、CCTCCGC、CCTCTTT、CCTGAGT、CCTGCTA、CCTGCTG、CCTGTAA、CCTGTGA、CCTTCAT、CGAACAA、CGAACTT、CGATCCC、CGCAAAA、CGCAGCC、CGCGCCT、CGCTGCT、CGGTACG、CGGTGCT、CGGTGTG、CGTCACT、CGTCTTA、CTACAGT、CTACCTC、CTACTAG、CTACTGT、CTAGACC、CTAGGAA、CTATGAT、CTATGCA、CTCAAGA、CTCAGGG、CTCCAAG、CTCCTCC、CTCTAGA、CTCTATG、CTCTGGA、CTGAGCC、CTGTAAG、CTGTCAC、CTGTTAC、CTGTTGA、CTGTTTT、CTTACCC、CTTGTAT、CTTTGCA、CTTTGTA、GAACCAA、GAATGTG、GACAATC、GACACAA、GACAGGG、GACCAAC、GACCGCG、GACCTTC、GACTGTT、GAGACGC、GAGACGG、GAGACTG、GAGCAAT、GAGCCAG、GAGCCTG、GAGCGGA、GAGCGGT、GAGCTGG、GAGGACG、GAGTGAC、GATAGGG、GATCCCA、GATCCCC、GATTTTT、GCAAAAA、GCAAGAC、GCAAGGA、GCACAAT、GCACACT、GCACCTT、GCACTTT、GCAGACA、GCAGCCA、GCAGCGA、GCAGCTC、GCAGGCT、GCATACA、GCATCCT、GCATTTG、GCCACAC、GCCCAAG、GCCCACC、GCGCACG、GCGCCAT、GCGCCTT、GCGCTTT、GCTACTT、GCTAGTT、GCTCTTG、GCTGAGT、GCTGCTG、GCTGGAG、GCTTGAA、GCTTGTC、GGAAGTC、GGACTAG、GGATCCG、GGCACAT、GGCACTT、GGCAGAC、GGCAGCT、GGCAGTG、GGCCAGT、GGCCTGG、GGCGGCA、GGCTCGG、GGCTTCC、GGGACCA、GGGAGAA、GGGATGC、GGGATTT、GGGCATT、GGGGCCC、GGTAACC、GGTGAAG、GGTGTGT、GGTTATG、GGTTCTT、GGTTTTT、GTAAACC、GTAAGAC、GTAAGAT、GTACAGG、GTACGAT、GTACTGG、GTACTGT、GTAGGCA、GTAGGGT、GTATGAT、GTATTAT、GTATTCT、GTCAACC、GTCACAA、GTCAGGA、GTCCTCG、GTCCTCT、GTCGATC、GTCTACC、GTCTACT、GTCTTCC、GTGACAC、GTGACTT、GTGCAAA、GTGCAAT、GTGCCAA、GTGCCAT、GTGCCTT、GTGGCCA、GTGGTGA、GTGGTGC、GTGTCAA、GTGTCAT、GTGTGAG、GTGTGCG、GTGTTGA、GTTAAAG、GTTATAT、GTTTAGC、GTTTGTT、TAATAAT、TAATGTG、TACAATC、TACGCCC、TACGGGT、TACTTGA、TAGAACC、TAGAGTT、TAGCTTT、TAGGTCA、TATCATA、TATCTGG、TATGGAA、TATTATA、TCACCTT、TCAGGTT、TCATCTC、TCCACCC、TCCAGAG、TCCAGAT、TCCAGGT、TCCCCAC、TCCCGTT、TCCGTCC、TCCTTCC、TCGATGG、TCTAGAG、TCTATGA、TCTCTCC、TCTGATA、TCTGATC、TCTGGAC、TCTGGTG、TGAATGT、TGACACA、TGAGATT、TGAGCAG、TGAGCGT、TGCAAAC、TGCACGA、TGCACTG、TGCACTT、TGCAGAA、TGCCCAG、TGCCTCC、TGCCTTA、TGCTAGC、TGCTGCT、TGCTGGT、TGCTTTG、TGGATCA、TGGGATC、TGGGTCG、TGGTACT、TGGTGCC、TGGTGCT、TGTATGA、TGTATTA、TGTGTGA、TGTTACT、TGTTCTG、TGTTTAC、TGTTTCA、TTACTAG、TTACTTT、TTAGCTC、TTATACA、TTCAACG、TTCCCCC、TTCCCGA、TTCCGTT、TTGCACT、TTGCCAA、TTGCTGA、TTGGAGA、TTGGGAG、TTTATCT、TTTGCAC、TTTGTAG、およびTTTTGAG。
  44. 連続核酸塩基配列が以下からなる群から選択される配列からなるかまたはかかる配列を含む請求項1-7のいずれかのオリゴマー: AAAACCAC、AAAAGACA、AAACACCC、AAACCATA、AAACCATC、AAACTGAC、AAACTGGA、AAAGCCAT、AAATGGAG、AACAAAAC、AACAACTT、AACACAAG、AACACTAC、AACACTGG、AACATATC、AACATTCC、AACCAAAG、AACCATTT、AACGTGGG、AACTACCT、AACTGGCT、AAGACACG、AAGCACTT、AAGCATTA、AAGCGCAG、AAGCGCGT、AAGCGCTT、AAGGAAGC、AAGGCACT、AAGTCTTA、AAGTGCGT、AATAAGCT、AATGAAGG、AATGCTGC、AATGTAGC、AATTAGAA、AATTCTTT、AATTTCTC、ACAACACC、ACAACACT、ACAATGCA、ACACCAGC、ACACTGCC、ACAGAATT、ACAGCACT、ACAGTATT、ACAGTGTT、ACATTTCA、ACCACAGG、ACCACCCC、ACCCAGGC、ACCGTGCC、ACGAACAA、ACGGTACG、ACGGTGTG、ACTACAGT、ACTACCTC、ACTACTGT、ACTATGAT、ACTATGCA、ACTCCAAG、ACTGAGCC、AGAATGTG、AGACCTTC、AGACTGTT、AGAGCAAT、AGATCCCA、AGATTTTT、AGCAAGGA、AGCACTTT、AGCAGACA、AGCAGCTC、AGCATTTG、AGCCACAC、AGCGCCTT、AGCGCTTT、AGCTACTT、AGGACTAG、AGGCACAT、AGGCACTT、AGGCCAGT、AGGCTCGG、AGGTGAAG、AGGTGTGT、AGGTTCTT、AGTAAGAC、AGTACAGG、AGTACTGT、AGTAGGCA、AGTATTCT、AGTCAGGA、AGTCTACC、AGTCTTCC、AGTGACAC、AGTGACTT、AGTGCAAT、AGTGCCAA、AGTGCCAT、AGTGGTGC、AGTGTCAA、AGTGTTGA、ATACGCCC、ATAGGTCA、ATCAGGTT、ATCCACCC、ATCTAGAG、ATGAATGT、ATGAGCAG、ATGAGCGT、ATGCACGA、ATGCACTG、ATGCACTT、ATGCAGAA、ATGGGATC、ATGGGTCG、ATGGTGCT、ATGTATTA、ATGTTTAC、ATTCCCGA、ATTCCGTT、ATTGCACT、ATTGCCAA、ATTTGCAC、ATTTTGAG、CAAAAGAT、CAAACTGT、CAAAGGAT、CAAAGGGA、CAAATGAA、CAACATTC、CAACTGTA、CAAGCACA、CAAGGCAT、CAAGGGAT、CAAGTCCA、CAAGTGGA、CAAGTTAC、CAATGCAT、CAATGGGT、CAATGTGA、CACAAGAA、CACACTCC、CACAGGTT、CACCGTTT、CACGCACA、CACTAGGT、CACTGCAG、CACTGCCT、CACTGTAG、CACTGTGA、CAGAAAAT、CAGAATAC、CAGACAGC、CAGACCGC、CAGCACTT、CAGCATTT、CAGCCTAG、CAGCTGCT、CAGCTGGG、CAGGCGCC、CAGGCGTT、CAGGTGCA、CAGTAGTT、CAGTCTAG、CAGTGTGT、CAGTTCTC、CATACAAG、CATAGGAA、CATATGCA、CATCAGGT、CATCATGA、CATCTTGC、CATGGTGC、CATGTACA、CATGTTAA、CATTCTCA、CCAAGGAT、CCACGTTT、CCACTAAG、CCACTCTA、CCAGATGG、CCAGCAGG、CCAGCCTC、CCAGCTTT、CCAGGGTC、CCAGTCAC、CCAGTTTT、CCATGGTC、CCATGTAA、CCCAGGGG、CCCATCCC、CCCGTTGA、CCCTCCGC、CCCTGTGA、CCGCAGCC、CCGCTGCT、CCGTCACT、CCTACCTC、CCTACTAG、CCTAGACC、CCTCAAGA、CCTCTAGA、CCTCTATG、CCTCTGGA、CCTTGTAT、CCTTTGCA、CCTTTGTA、CGAGACGC、CGAGCGGA、CGAGTGAC、CGATCCCC、CGCAAAAA、CGCAGCGA、CGGATCCG、CGTAGGGT、CGTCCTCT、CGTGCAAA、CGTGCAAT、CGTGTCAT、CTACAATC、CTACGGGT、CTAGAACC、CTAGCTTT、CTATCATA、CTATGGAA、CTCCAGAG、CTCCAGAT、CTCCGTCC、CTCTATGA、CTCTGGAC、CTGAGATT、CTGCAAAC、CTGCCCAG、CTGCCTCC、CTGGATCA、CTGGTACT、CTGGTGCC、CTTACTAG、CTTCAACG、CTTTGTAG、GAAACCGT、GAACATAC、GAACCTGC、GAAGCACT、GAAGTGTT、GAATCTAC、GACAACCT、GACCGAGC、GACTGAAA、GAGACTCA、GAGAGGGA、GAGCCAGC、GAGCTCAT、GAGCTCCT、GAGGAGTG、GAGGGCCA、GAGGTCTC、GAGTCAGC、GATAACCT、GATAAGCT、GATCCCCG、GATGACGT、GATGCACG、GATGCAGT、GATGCTGG、GATGTAGC、GATGTCAC、GATTGTGA、GATTTGAA、GCAAGCAC、GCAAGGGA、GCAATGCA、GCACACTT、GCACTTTG、GCAGACTG、GCAGGTCC、GCAGTATT、GCATTGTG、GCCAACTC、GCCAGGTC、GCCATCCA、GCCCAGAG、GCCCCCAG、GCCCCGCC、GCCCGTGT、GCCTGCTA、GCCTGCTG、GCCTTCAT、GCGAACTT、GCGATCCC、GCGGTGCT、GCTGTTAC、GCTGTTTT、GCTTACCC、GGACAATC、GGACAGGG、GGACCAAC、GGAGCCAG、GGAGCTGG、GGAGGACG、GGCACAAT、GGCACTTT、GGCAGGCT、GGCATACA、GGCATCCT、GGCCCACC、GGCGCACG、GGCGCCAT、GGCTAGTT、GGCTGAGT、GGCTGGAG、GGCTTGAA、GGCTTGTC、GGGAAGTC、GGGCAGAC、GGGCAGTG、GGGCCAGT、GGGCTTCC、GGGGACCA、GGGGATGC、GGGGCATT、GGGGGCCC、GGGTAACC、GGTAAACC、GGTAAGAT、GGTACTGG、GGTCAACC、GGTCACAA、GGTCCTCG、GGTCGATC、GGTCTACT、GGTGCAAA、GGTGCCTT、GGTGGTGA、GGTGTGCG、GGTTTAGC、GTAATAAT、GTAATGTG、GTAGAGTT、GTATTATA、GTCCAGGT、GTCCTTCC、GTCGATGG、GTGCACTG、GTGCCTTA、GTGCTGCT、GTGCTGGT、GTGCTTTG、GTGGGTCG、GTGTATGA、GTTGGGAG、GTTTTGAG、TAAACTTT、TAACGGTT、TAAGCAAT、TAAGTCCA、TACAGGGT、TACATTCC、TACCAATC、TACTATTA、TACTTTAT、TAGCATTA、TAGGGCAG、TAGTTGTC、TATAATAT、TATACCCA、TATACCTC、TATACTGT、TATCCTAA、TATCTCCA、TATGTCTT、TATGTTTC、TATTACAT、TCACCTGT、TCACTGTG、TCACTTCA、TCATTAAC、TCCACACA、TCCAGGTT、TCCATGTC、TCCCACAT、TCCTCCAA、TCCTCTTT、TCCTGAGT、TCCTGTAA、TCGCAAAA、TCGCGCCT、TCGTCTTA、TCTAGGAA、TCTCAGGG、TCTCCTCC、TCTGTAAG、TCTGTCAC、TCTGTTGA、TGAACCAA、TGACACAA、TGACCGCG、TGAGACGG、TGAGACTG、TGAGCCTG、TGAGCGGT、TGATAGGG、TGCAAGAC、TGCACACT、TGCACCTT、TGCAGCCA、TGCCCAAG、TGCTCTTG、TGCTGCTG、TGGCAGCT、TGGCCTGG、TGGCGGCA、TGGGAGAA、TGGGATTT、TGGTTATG、TGGTTTTT、TGTACGAT、TGTATGAT、TGTATTAT、TGTCAACC、TGTGCAAT、TGTGGCCA、TGTGTGAG、TGTTAAAG、TGTTATAT、TGTTTGTT、TTACTTGA、TTATCTGG、TTCACCTT、TTCATCTC、TTCCCCAC、TTCCCGTT、TTCTCTCC、TTCTGATA、TTCTGATC、TTCTGGTG、TTGAATGT、TGACACA、TTGCTAGC、TTGCTGCT、TTGTGTGA、TTGTTACT、TTGTTCTG、TTGTTTCA、TTTACTTT、TTTAGCTC、TTTATACA、TTTCCCCC、TTTGCTGA、TTTGGAGA、およびTTTTATCT。
  45. オリゴマーが7つのLNA 核酸塩基の連続核酸塩基配列からなり、すべてのヌクレオシド間結合がホスホロチオエートである請求項1 - 44のいずれかのオリゴマー。
  46. オリゴマーが8つのLNA 核酸塩基の連続核酸塩基配列からなり、すべてのヌクレオシド間結合がホスホロチオエートである請求項1 - 44のいずれかのオリゴマー。
  47. オリゴマーが9つのLNA 核酸塩基の連続核酸塩基配列からなり、すべてのヌクレオシド間結合がホスホロチオエートである請求項1 - 44のいずれかのオリゴマー。
  48. オリゴマーが10のLNA 核酸塩基の連続核酸塩基配列からなり、すべてのヌクレオシド間結合がホスホロチオエートである請求項1 - 44のいずれかのオリゴマー。
  49. 医薬として使用するための請求項1-48のいずれかのオリゴマー。
  50. 細胞におけるマイクロRNAターゲットの有効量を減少させるためのインビトロでの方法であって、請求項1 - 48のいずれかのオリゴマーを含む組成物を、細胞におけるマイクロRNAの有効量を減少させるために投与することを含む方法。
JP2010527323A 2007-10-04 2008-10-03 マイクロｍｉｒ Active JP6035010B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US97749707P 2007-10-04 2007-10-04
US60/977,497 2007-10-04
US97921707P 2007-10-11 2007-10-11
US60/979,217 2007-10-11
US2806208P 2008-02-12 2008-02-12
US61/028,062 2008-02-12
EP08104780.5 2008-07-17
EP08104780 2008-07-17
PCT/DK2008/000344 WO2009043353A2 (en) 2007-10-04 2008-10-03 Micromirs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015011745A Division JP6231029B2 (ja) 2007-10-04 2015-01-23 マイクロｍｉｒ

Publications (3)

Publication Number Publication Date
JP2010539959A JP2010539959A (ja) 2010-12-24
JP2010539959A5 true JP2010539959A5 (ja) 2011-11-17
JP6035010B2 JP6035010B2 (ja) 2016-11-30

Family

ID=40526747

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010527323A Active JP6035010B2 (ja) 2007-10-04 2008-10-03 マイクロｍｉｒ
JP2015011745A Active JP6231029B2 (ja) 2007-10-04 2015-01-23 マイクロｍｉｒ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015011745A Active JP6231029B2 (ja) 2007-10-04 2015-01-23 マイクロｍｉｒ

Country Status (17)

Country Link
US (5) US8288356B2 (ja)
EP (5) EP3492594A1 (ja)
JP (2) JP6035010B2 (ja)
KR (1) KR101889518B1 (ja)
CN (1) CN101821391B (ja)
AU (1) AU2008306327B2 (ja)
CA (1) CA2701547C (ja)
DK (2) DK2623599T3 (ja)
EA (1) EA019939B1 (ja)
ES (3) ES2463665T3 (ja)
IL (2) IL204254A (ja)
MX (1) MX2010003299A (ja)
MY (1) MY156951A (ja)
NZ (1) NZ583677A (ja)
PL (1) PL2623598T3 (ja)
WO (2) WO2009043354A2 (ja)
ZA (1) ZA201002040B (ja)

Families Citing this family (242)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
CA2564503C (en) 2004-05-04 2015-12-29 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of mir-122 in hepatitis c virus infected subjects and cells
ES2461189T3 (es) 2006-01-05 2014-05-19 The Ohio State University Research Foundation Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos de mama o pulmón
EP2369012A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Micro-RNA fingerprints during human megakaryocytopoiesis
EA201100813A1 (ru) 2006-04-03 2012-06-29 Сантарис Фарма А/С Фармацевтическая композиция
CA3042781C (en) 2006-04-03 2021-10-19 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
CA2681568C (en) * 2006-11-23 2019-01-08 Querdenker Aps Oligonucleotides for modulating target rna activity
US8697672B2 (en) * 2007-05-16 2014-04-15 California Institute Of Technology Microrna inhibition for the treatment of inflammation and myeloproliferative disorders
CN101821390A (zh) * 2007-06-14 2010-09-01 米尔克斯治疗有限责任公司 用于调节靶rna活性的寡核苷酸
EP2187896B1 (en) 2007-07-31 2016-01-13 The Board of Regents of The University of Texas System Inhibitors of mir-499 and mir-208b for use in the treatment of pathologic cardiac hypertrophy, heart failure or myocardial infarction
NZ583024A (en) 2007-07-31 2012-04-27 Regents The Univeristy Of Texas System Board Of An agonist of miR-29a, miR-29b or miR-29c that prevents tissue fibrosis and uses thereof
ES2627059T3 (es) 2007-08-03 2017-07-26 The Ohio State University Research Foundation Regiones ultraconservadas que codifican ARNnc
ES2463665T3 (es) * 2007-10-04 2014-05-28 Stella Aps Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
WO2009058907A2 (en) * 2007-10-29 2009-05-07 Isis Pharmaceuticals, Inc. Targeting micrornas for the treatment of liver cancer
WO2009062169A2 (en) 2007-11-09 2009-05-14 The Board Of Regents Of The University Of Texas System Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair
US20110257244A1 (en) * 2008-01-18 2011-10-20 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
CN102007223B (zh) * 2008-02-28 2014-06-18 俄亥俄州立大学研究基金会 用于胃癌的诊断、预后和治疗的基于微rna的方法和组合物
EP3112477A1 (en) * 2008-02-28 2017-01-04 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of prostate related disorders
US8361980B2 (en) 2008-03-07 2013-01-29 Santaris Pharma A/S Pharmaceutical compositions for treatment of microRNA related diseases
CA2718520C (en) 2008-03-17 2020-01-07 The Board Of Regents Of The University Of Texas System Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
EP2274423A2 (en) 2008-04-04 2011-01-19 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
ES2541442T3 (es) 2008-08-01 2015-07-20 Roche Innovation Center Copenhagen A/S Modulación mediada por microARN de factores estimulantes de colonias
US9068232B2 (en) * 2008-08-06 2015-06-30 Rosetta Genomics Ltd. Gene expression signature for classification of kidney tumors
CA2746527A1 (en) * 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Rna interference in skin indications
JP5793423B2 (ja) * 2008-12-31 2015-10-14 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ 急性冠症候群の治療のためのＬＮＡＡｐｏＢアンチセンスオリゴマーの使用
EP2393945A4 (en) 2009-02-04 2013-08-07 Univ Texas DOUBLE TARGETING OF MIR-208 AND MIR-499 IN THE TREATMENT OF CARDIAC DISORDERS
EP2401406A4 (en) * 2009-02-25 2012-09-19 Cepheid METHODS OF DETECTING LUNG CANCER
EP2421970B1 (en) 2009-04-24 2016-09-07 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
EP2432880A1 (en) 2009-05-20 2012-03-28 ETH Zürich Targeting micrornas for metabolic disorders
WO2010135714A2 (en) * 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
CN102803284B (zh) * 2009-06-08 2015-11-25 米拉根医疗公司 用于miRNA抑制剂和模拟物的化学修饰基序
WO2011017089A1 (en) * 2009-07-27 2011-02-10 The Regents Of The University Of Colorado, A Body Corporate Mirna inhibition of six1 expression
WO2011016714A1 (en) * 2009-08-06 2011-02-10 Umc Utrecht Holding B.V. Means and methods for counteracting, delaying and/or preventing adverse energy metabolism switches in heart disease
WO2011021177A2 (en) 2009-08-19 2011-02-24 Rosetta Genomics Ltd. Compositions and methods for prognosis and treatment of prostate cancer
FR2953220B1 (fr) * 2009-12-01 2012-11-23 Oreal Signature microarn de la differenciation epidermique et utilisations
WO2011027893A1 (ja) * 2009-09-07 2011-03-10 Murakami Yoshiki 慢性c型肝炎の治療効果予測方法
US20120231970A1 (en) * 2009-09-30 2012-09-13 Japan Health Sciences Foundation Colon cancer marker and method for testing for colon cancer
WO2011048125A1 (en) 2009-10-20 2011-04-28 Santaris Pharma A/S Oral delivery of therapeutically effective lna oligonucleotides
WO2011060100A1 (en) * 2009-11-11 2011-05-19 Sanford-Burnham Medical Research Institute Method for generation and regulation of ips cells and compositions thereof
CN101798594A (zh) * 2009-11-13 2010-08-11 北京命码生科科技有限公司 检测牛乳质量的标志物、检测方法、生物芯片和试验盒
EP2504452A4 (en) 2009-11-23 2014-06-11 Univ Ohio State Res Found SUBSTANCES AND METHODS THAT CAN BE USED TO ACT ON THE GROWTH, MIGRATION, AND INVASION OF TUMOR CELLS
US20120302626A1 (en) * 2009-12-04 2012-11-29 Sandeep Dave Microrna and use thereof in identification of b cell malignancies
US20110171323A1 (en) * 2010-01-09 2011-07-14 The Translational Genomics Research Institute Methods and kits to predict prognostic and therapeutic outcome in small cell lung cancer
US8841269B2 (en) * 2010-02-23 2014-09-23 Creighton University Polynucleotides for use in treating and diagnosing cancers
US9624491B2 (en) 2010-02-26 2017-04-18 Memorial Sloan Kettering Cancer Center Methods and compositions for the detection and treatment of cancer involving miRNAs and miRNA inhibitors and targets
ES2743600T3 (es) 2010-03-12 2020-02-20 Brigham & Womens Hospital Inc Métodos de tratamiento de los trastornos inflamatorios vasculares
WO2011131354A1 (en) * 2010-04-20 2011-10-27 Febit Holding Gmbh Complex mirna sets as novel biomarkers for an acute coronary syndrome
CN102140462B (zh) * 2010-04-29 2013-06-12 苏州吉玛基因股份有限公司 人miR-1260反义核酸及其应用
WO2011146937A1 (en) * 2010-05-21 2011-11-24 The Translational Genomics Research Institute Methods and kits useful in diagnosing nsclc
EP2576785A4 (en) * 2010-06-04 2014-12-24 Univ Texas REGULATION OF METABOLISM BY MIR-378
US20120015830A1 (en) * 2010-06-21 2012-01-19 Diogenix, Inc. Microrna profiles for evaluating multiple sclerosis
AU2011274619B2 (en) 2010-07-06 2016-11-10 Interna Technologies Bv miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
CN102002494B (zh) * 2010-07-08 2012-12-12 浙江理工大学 microRNA生物标志物及其用途
US8815826B2 (en) 2010-07-23 2014-08-26 Regulus Therapeutics, Inc. Targeting microRNAs for the treatment of fibrosis
GB201012418D0 (en) 2010-07-23 2010-09-08 Santaris Pharma As Process
EP2608812B1 (en) 2010-08-25 2018-08-15 The General Hospital Corporation Nucleic acids targeting mir-33 micrornas for regulating lipid metabolism
CN102399852A (zh) * 2010-09-08 2012-04-04 上海市公共卫生临床中心 用于预测干扰素治疗慢性乙型肝炎疗效的血浆miRNA谱及检测试剂盒
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
WO2012065143A1 (en) 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas
AU2011326032B2 (en) 2010-11-12 2016-10-06 The Ohio State University Research Foundation Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer
BR112013011942A2 (pt) 2010-11-15 2016-11-01 Univ Michigan formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida.
BR112013012319A2 (pt) 2010-12-15 2019-09-24 Miragen Therapeutics inibidores de micro rna compreendendo nucleotídeos bloqueados
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
US9045749B2 (en) 2011-01-14 2015-06-02 The General Hospital Corporation Methods targeting miR-128 for regulating cholesterol/lipid metabolism
CN103703142A (zh) * 2011-01-26 2014-04-02 西菲伊德公司 检测肺癌的方法
CN102643810B (zh) * 2011-02-18 2015-12-16 中国科学院上海药物研究所 人miR-299-5p的反义寡聚核苷酸及其应用
CN102643813B (zh) * 2011-02-18 2015-07-29 中国科学院上海药物研究所 人miR-504的反义寡聚核苷酸及其应用
CN102643806B (zh) * 2011-02-18 2016-08-03 中国科学院上海药物研究所 人miR-1913的反义寡聚核苷酸及其应用
CN102643811B (zh) * 2011-02-18 2015-12-09 中国科学院上海药物研究所 人miR-1229的反义寡聚核苷酸及其应用
CN102643808B (zh) * 2011-02-18 2016-01-20 中国科学院上海药物研究所 人miR-1539的反义寡聚核苷酸及其应用
CN102643809B (zh) * 2011-02-18 2016-01-20 中国科学院上海药物研究所 人miR-1274b的反义寡聚核苷酸及其应用
CN102643814B (zh) * 2011-02-18 2015-06-17 中国科学院上海药物研究所 人miR-431的反义寡聚核苷酸及其应用
CA2832818A1 (en) * 2011-04-06 2012-10-11 The Trustees Of Princeton University Anti-viral combination therapy
WO2012145374A1 (en) 2011-04-19 2012-10-26 Regulus Therapeutics Inc. TARGETING miR-378 FAMILY MEMBERS FOR THE TREATMENT OF METABOLIC DISORDERS
ES2868950T3 (es) * 2011-04-25 2021-10-22 Sanofi Sa Compuestos de microARN y métodos para modular la actividad de miR-21
US9241950B2 (en) * 2011-04-28 2016-01-26 New York University MiR-33 inhibitors and uses thereof to decrease inflammation
KR101800243B1 (ko) 2011-06-22 2017-12-20 (주)아모레퍼시픽 마이크로 ｒｎａ를 포함하는 색소형성유전자 발현조절용 조성물
US20140127159A1 (en) 2011-06-23 2014-05-08 Stella Aps HCV Combination Therapy
US20140194491A1 (en) * 2011-06-24 2014-07-10 Syddansk Universitet Modulation of microrna-138 for the treatment of bone loss
US20140113958A1 (en) * 2011-06-30 2014-04-24 Stella Aps HCV Combination Therapy
KR20140058536A (ko) 2011-06-30 2014-05-14 스텔라 에이피에스 Hcv 조합 치료
CN102851282B (zh) * 2011-06-30 2014-10-08 上海市肿瘤研究所 用于区分原发性肺癌与癌旁组织的microRNA标志物
WO2013013165A2 (en) * 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
US9617538B2 (en) * 2011-08-29 2017-04-11 Niigata University Of Pharmacy And Applied Life Science Heptamer-type small guide nucleic acids inducing apoptosis of human leukemia cells
CA2844577A1 (en) * 2011-09-13 2013-03-21 Ottawa Hospital Research Institute Microrna inhibitors
US9580708B2 (en) 2011-09-14 2017-02-28 Rana Therapeutics, Inc. Multimeric oligonucleotides compounds
EP2763703B1 (en) 2011-10-06 2018-02-14 Miragen Therapeutics, Inc. Control of whole body energy homeostasis by microrna regulation
US10184151B2 (en) 2011-10-11 2019-01-22 The Brigham And Women's Hospital, Inc. Micrornas in neurodegenerative disorders
JP2014530612A (ja) 2011-10-14 2014-11-20 ジ・オハイオ・ステート・ユニバーシティ 卵巣がんに関する方法および材料
WO2013068348A1 (en) 2011-11-07 2013-05-16 Santaris Pharma A/S Lna oligomers for improvement in hepatic function
CA2853328A1 (en) 2011-11-07 2013-05-16 Stella Aps Prognostic method for checking efficacy of micro rna-122 inhibitors in hcv+ patients
JP2015504847A (ja) * 2011-11-30 2015-02-16 シーダーズ−サイナイ メディカル センター 前立腺癌骨転移および薬剤耐性肺癌を治療するためのマイクロｒｎａｍｉｒ−４０９−５ｐ、ｍｉｒ−３７９、およびｍｉｒ−１５４＊の標的化
US9745578B2 (en) 2011-11-30 2017-08-29 Cedars-Sinai Medical Center Targeting microRNA miR-409-3P to treat prostate cancer
AU2012347498A1 (en) * 2011-12-10 2014-06-26 Ohio State Innovation Foundation MiRNAs useful to reduce lung cancer tumorigenesis and chemotherapy resistance and related compositons and methods
CN104619353A (zh) 2011-12-13 2015-05-13 俄亥俄州国家创新基金会 与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移
EP2816114A3 (en) * 2011-12-15 2015-02-25 Oncostamen S.r.l. MicroRNAs and uses thereof
US10519506B2 (en) * 2011-12-22 2019-12-31 Baylor Research Institute Identification of metastasis-specific miRNA and hypomethylation signatures in human colorectal cancer
JP2015511121A (ja) 2012-01-20 2015-04-16 ジ・オハイオ・ステート・ユニバーシティ 浸潤性および予後に関する乳がんバイオマーカーシグネチャー
WO2013134403A1 (en) * 2012-03-06 2013-09-12 The Washington University Method of treating neurodegenerative diseases with microrna regulators
US8969317B2 (en) 2012-04-25 2015-03-03 Regulus Therapeutics Inc. MicroRNA compounds and methods for modulating miR-21 activity
US9334498B2 (en) 2012-05-10 2016-05-10 Uab Research Foundation Methods and compositions for modulating MIR-204 activity
AU2013262699A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating ATP2A2 expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
EA201492116A1 (ru) 2012-05-16 2015-05-29 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии mecp2
AP2014008100A0 (en) 2012-05-16 2014-12-31 Gen Hospital Corp Compositions and methods for modulating hemoglobingene family expression
EP3511416A1 (en) 2012-05-16 2019-07-17 Translate Bio MA, Inc. Compositions and methods for modulating gene expression
SG11201407486PA (en) 2012-05-16 2014-12-30 Rana Therapeutics Inc Compositions and methods for modulating utrn expression
AU2013262649A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating smn gene family expression
WO2013192576A2 (en) 2012-06-21 2013-12-27 Miragen Therapeutics Oligonucleotide-based inhibitors comprising locked nucleic acid motif
US9163235B2 (en) * 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
CN116271053A (zh) 2012-08-13 2023-06-23 洛克菲勒大学 治疗和诊断黑素瘤
CN103627704A (zh) * 2012-08-30 2014-03-12 苏州博泰安生物科技有限公司 前列腺癌分子标志物miR-19a及其应用
WO2014043544A1 (en) 2012-09-14 2014-03-20 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
WO2014059126A1 (en) * 2012-10-10 2014-04-17 Beth Israel Deaconess Medical Center, Inc. Biomarkers and treatments for heart failure
US9267139B2 (en) 2012-10-11 2016-02-23 Georgia Regents Research Institute, Inc. Compositions and methods for treating musculoskeletal diseases and disorders
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
WO2014071205A1 (en) * 2012-11-02 2014-05-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for diagnosis, prognosis and treatment of hematological malignancies
US9909128B2 (en) * 2012-11-15 2018-03-06 The Regents Of The University Of California Splice modulating oligonucleotides that inhibit cancer
CN104837996A (zh) 2012-11-15 2015-08-12 罗氏创新中心哥本哈根有限公司 抗apob反义缀合物化合物
WO2014075822A1 (en) 2012-11-16 2014-05-22 Siemens Aktiengesellschaft New diagnostic mirna markers for parkinson disease
EP2733219B1 (en) 2012-11-16 2017-09-20 Siemens Aktiengesellschaft Diagnostic miRNA markers for Alzheimer
EP2733220B1 (en) * 2012-11-16 2017-10-18 Siemens Aktiengesellschaft Novel miRNA as a diagnostic marker for Alzheimer's Disease
EP2943570B1 (en) 2013-01-14 2018-01-03 Pierfrancesco Tassone Inhibitors of mirnas 221 and 222 for anti-tumor activity in multiple myeloma
HUE032125T2 (en) * 2013-01-24 2017-08-28 Pierre Fabre Medicament S A S Preparation containing encapsulated antagomir
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
CA2893801A1 (en) 2013-01-30 2014-08-07 F. Hoffmann-La Roche Ag Lna oligonucleotide carbohydrate conjugates
US20160145612A1 (en) * 2013-03-06 2016-05-26 Royal College Of Surgeons In Ireland Diagnosis and treatment of metabolic disorders
KR101465319B1 (ko) * 2013-03-08 2014-11-28 서울대학교산학협력단 마이크로 rna 분해 엘리먼트 및 그 용도
US9752143B2 (en) 2013-03-15 2017-09-05 MiRagen Therapeutics, Inc. Locked nucleic acid inhibitor of miR-145 and uses thereof
WO2014145142A2 (en) * 2013-03-15 2014-09-18 Miles Gregory Method of improving survival in cancer
AU2014259953B2 (en) 2013-05-01 2020-07-02 Regulus Therapeutics Inc. Compounds and methods for enhanced cellular uptake
WO2014179446A2 (en) * 2013-05-01 2014-11-06 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-122
CN103290010B (zh) * 2013-05-16 2015-09-16 南京市妇幼保健院 与胎儿先天性心脏病相关的母体血清/血浆miRNA标志物mir-375及其应用
WO2014201301A1 (en) * 2013-06-12 2014-12-18 New York University Anti-mir-27b and anti-mir-148a oligonucleotides as therapeutic tools for treating dyslipidemias and cardiovascular diseases
WO2014201314A1 (en) * 2013-06-14 2014-12-18 Joslin Diabetes Center, Inc. Microrna and uses in brown fat differentiation
WO2014210041A1 (en) 2013-06-25 2014-12-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Service Glucan-encapsulated sirna for treating type 2 diabetes mellitus
EP3591054A1 (en) 2013-06-27 2020-01-08 Roche Innovation Center Copenhagen A/S Antisense oligomers and conjugates targeting pcsk9
US11478504B2 (en) 2013-07-08 2022-10-25 International Dehydrated Foods, Inc. Compositions and methods for preventing/treating metabolic syndrome
WO2015006287A2 (en) * 2013-07-08 2015-01-15 International Dehydrated Foods, Inc. Compositions prepared from poultry and methods of their use
CN104342439B (zh) * 2013-07-23 2017-06-23 中国科学院遗传与发育生物学研究所 miR‑7及其应用
WO2015051283A1 (en) 2013-10-04 2015-04-09 Rana Therapeutics, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
EP3060664B1 (en) 2013-10-25 2021-07-07 Sanofi Microrna compounds and methods for modulating mir-21 activity
DK3091987T3 (en) * 2014-01-08 2018-08-06 Hadasit Medical Res Services And Development miR-122 * as active micro-RNA, compositions comprising the same and their use
CN104774914B (zh) * 2014-01-09 2018-01-09 复旦大学附属儿科医院 胆道闭锁及淤胆型婴儿肝炎综合征的microRNA血清标志物检测及其应用
EP3091970B1 (en) 2014-01-10 2020-10-28 Rgenix, Inc. Lxr agonists and uses thereof
CN104974987B (zh) * 2014-04-04 2018-06-19 宁夏医科大学 微小分子RNA-1247-5p作为新型肿瘤治疗分子靶标的用途
CN103937888B (zh) * 2014-04-14 2016-08-17 上海交通大学 鉴别胃癌的血浆microRNA标志物的筛选与应用
CN103940998B (zh) * 2014-05-04 2016-04-20 山东大学 血清microRNA作为肝细胞癌转移的早期诊断标志物的应用
CA2948224A1 (en) * 2014-06-13 2015-12-17 Universitat Fur Bodenkultur Wien Compositions and methods for the diagnosis and treatment of bone fractures and disorders
EP3760208B1 (en) 2014-06-25 2024-05-29 The General Hospital Corporation Targeting human satellite ii (hsatii)
EP3177722A4 (en) * 2014-07-31 2018-01-17 Agency For Science, Technology And Research Modified antimir-138 oligonucleotides
AU2015301221B2 (en) 2014-08-04 2020-07-02 MiRagen Therapeutics, Inc. Inhibitors of MYH7B and uses thereof
KR20170033439A (ko) 2014-08-07 2017-03-24 레굴루스 테라퓨틱스 인크 대사 장애에 대한 마이크로rna의 표적화
WO2016070060A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
US10206955B2 (en) * 2014-11-05 2019-02-19 Emory University Compositions of ascorbic acid and bone morphogenetic protein 4 (BMP-4) for cell growth and uses related thereo
US20180291374A1 (en) * 2014-11-12 2018-10-11 The General Hospital Corporation INHIBITORS OF MICRORNAs miR-155, miR-103, miR-105 and miR-107 THAT REGULATE PRODUCTION OF ATRIAL NATRIURETIC PEPTIDE (ANP) AS THERAPEUTICS AND USES THEREOF
EP3221452A4 (en) * 2014-11-21 2018-11-21 Caris Science, Inc. Oligonucleotide probes and uses thereof
JP2018504380A (ja) 2014-12-18 2018-02-15 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｒｅｖｅｒｓｉｒ（商標）化合物
CN107636003A (zh) 2015-01-20 2018-01-26 米拉根医疗股份有限公司 miR‑92抑制剂及其用途
WO2016130943A1 (en) 2015-02-13 2016-08-18 Rana Therapeutics, Inc. Hybrid oligonucleotides and uses thereof
WO2016138287A1 (en) 2015-02-25 2016-09-01 Washington University METHODS TO DETECT MOTOR NEURON DISEASE COMPRISING MICRO-RNAs
US11085044B2 (en) 2015-03-09 2021-08-10 University Of Kentucky Research Foundation miRNA for treatment of breast cancer
EP3271460A4 (en) 2015-03-17 2019-03-13 The General Hospital Corporation INTERACTOME RNA OF COMPLEX REPRESSIVE POLYCOMB 1 (PRC1)
WO2016160882A1 (en) * 2015-04-01 2016-10-06 Baylor Research Institute Methods for diagnosing and treating colorectal cancer using mirna549a
EP3283502A4 (en) 2015-04-07 2019-04-03 The General Hospital Corporation METHODS FOR REACTIVATION OF GENES ON INACTIVE X CHROMOSOME
CA2986913A1 (en) * 2015-06-05 2016-12-08 MiRagen Therapeutics, Inc. Mir-155 inhibitors for treating amyotrophic lateral sclerosis (als)
CN108138180A (zh) 2015-06-05 2018-06-08 米拉根医疗股份有限公司 用于治疗皮肤t细胞淋巴瘤（ctcl）的mir-155抑制剂
WO2016210241A1 (en) 2015-06-26 2016-12-29 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
CN108701922B (zh) 2015-07-07 2020-02-14 Afci亚洲私人有限公司 电连接器
KR20180039162A (ko) 2015-08-20 2018-04-17 아소시아시온 센트로 데 인베스티가시온 코오페라티바 엔 비오시엔시아스-시스 비오구네 간 질환 및 병태를 치료하기 위한 방법 및 조성물
KR20180043819A (ko) 2015-08-24 2018-04-30 로슈 이노베이션 센터 코펜하겐 에이/에스 Lna-g 방법
JP6893505B2 (ja) 2015-10-02 2021-06-23 ロシュ イノベーション センター コペンハーゲン エーエス オリゴヌクレオチドコンジュゲーション方法
WO2017066712A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
EP3394258B1 (en) 2015-10-22 2021-09-22 Roche Innovation Center Copenhagen A/S In vitro toxicity screening assay
WO2017087708A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
CA3054284A1 (en) 2016-02-25 2017-08-31 The Brigham And Women's Hospital, Inc. Treatment methods for fibrosis targeting smoc2
EP3430021A1 (en) 2016-03-18 2019-01-23 Roche Innovation Center Copenhagen A/S Acyl-protected l-lna-guanosine monomers
WO2017192959A2 (en) * 2016-05-05 2017-11-09 The Research Foundation For The State University Of New York Therapeutically modulating apob and apoai
DK3455232T3 (da) 2016-05-12 2020-07-06 Roche Innovation Ct Copenhagen As Forbedret kobling af stereodefinerede oxazaphospholidin-phosphoramidit-monomerer til nukleosid eller oligonukleotid
EP3254683A1 (en) 2016-06-06 2017-12-13 Medizinische Hochschule Hannover Medicament for the treatment of acute liver failure
CN109312403B (zh) 2016-06-17 2023-06-27 豪夫迈·罗氏有限公司 体外肾毒性筛选测定法
CN109328236B (zh) 2016-06-17 2022-10-25 豪夫迈·罗氏有限公司 体外肾毒性筛选测定法
EP3481430A4 (en) 2016-07-11 2020-04-01 Translate Bio Ma, Inc. NUCLEIC ACID CONJUGATES AND USES THEREOF
EP3532638A4 (en) 2016-10-31 2020-07-29 University of Massachusetts TARGETING MICROARN-101-3 P IN CARCINOTHERAPY
MX2019006332A (es) * 2016-12-05 2019-08-01 Regulus Therapeutics Inc Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal.
US11746381B2 (en) 2017-03-10 2023-09-05 Cancer Diagnostics Research Innvovations, LLC Methods for diagnosing and treating gastric cancer using miRNA expression
US11542294B2 (en) 2017-03-29 2023-01-03 Roche Innovation Center Copenhagen A/S Rapid unylinker cleavage
US11591362B2 (en) 2017-03-29 2023-02-28 Roche Innovation Center Copenhagen A/S Orthogonal protecting groups for the preparation of stereodefined phosphorothioate oligonucleotides
WO2018195486A1 (en) 2017-04-21 2018-10-25 The Broad Institute, Inc. Targeted delivery to beta cells
EP3645544B1 (en) 2017-06-28 2023-05-10 Roche Innovation Center Copenhagen A/S Multiple coupling&oxidation method
KR101871920B1 (ko) 2017-08-04 2018-07-02 (주)아모레퍼시픽 마이크로 ｒｎａ를 포함하는 조성물
WO2019073018A1 (en) 2017-10-13 2019-04-18 Roche Innovation Center Copenhagen A/S METHODS OF IDENTIFYING ANTISENSE OLIGONUCLEOTIDE IMPROVED OLIGONUCLEOTIDE PHOSPHOROTHIOATE STEREODEFINIS VARIANTS USING PARTIALLY STEREODEFINIS OLIGONUCLEOTIDE SUB LIBRARIES
WO2019084717A1 (en) 2017-10-30 2019-05-09 Amphenol Fci Asia Pte Ltd Low crosstalk card edge connector
EP3703669A4 (en) 2017-11-01 2021-11-10 Dana-Farber Cancer Institute, Inc. CANCER TREATMENT METHODS
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof
US10601181B2 (en) 2017-12-01 2020-03-24 Amphenol East Asia Ltd. Compact electrical connector
WO2019122277A1 (en) 2017-12-22 2019-06-27 Roche Innovation Center Copenhagen A/S Novel thiophosphoramidites
TW201934750A (zh) 2017-12-22 2019-09-01 丹麥商羅氏創新中心哥本哈根有限公司 包含二硫代磷酸酯核苷間連結之間隙子(gapmer)寡核苷酸
MX2020006430A (es) 2017-12-22 2020-09-17 Roche Innovation Ct Copenhagen As Oligonucleotidos que comprenden un enlace internucleosidico de fosforoditioato.
CN113116918B (zh) * 2017-12-29 2022-06-14 中国科学院上海药物研究所 靶向PCSK9的microRNA在治疗LDLC相关代谢性疾病中的应用
PE20201501A1 (es) 2018-01-12 2020-12-29 Bristol Myers Squibb Co Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos
CA3093844A1 (en) * 2018-03-14 2019-09-19 Beth Israel Deaconess Medical Center Micro-rna and obesity
US20210071180A1 (en) * 2018-04-23 2021-03-11 Board Of Regents, The Universy Of Texas System Microrna 584-5p compositions and methods for treating cancer
CN109321655B (zh) * 2018-05-17 2022-07-05 福建省肿瘤医院（福建省肿瘤研究所、福建省癌症防治中心） Nkiras2基因调控区序列、调控序列及其在鼻咽癌中的应用
EP3793685A1 (en) 2018-05-18 2021-03-24 F. Hoffmann-La Roche AG Pharmaceutical compositions for treatment of microrna related diseases
CN112236439A (zh) 2018-07-31 2021-01-15 罗氏创新中心哥本哈根有限公司 包含三硫代磷酸酯核苷间键的寡核苷酸
CA3105705A1 (en) 2018-07-31 2020-02-06 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
CN112585280A (zh) 2018-08-23 2021-03-30 罗氏创新中心哥本哈根有限公司 微小rna-134生物标志物
CA3110661A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
EP3620519A1 (en) 2018-09-04 2020-03-11 F. Hoffmann-La Roche AG Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
WO2020051398A1 (en) * 2018-09-06 2020-03-12 Aptamir Therapeutics, Inc. Metabolic benefits of short mir-22 mirna antagomir therapies
WO2020073460A1 (en) 2018-10-09 2020-04-16 Amphenol Commercial Products (Chengdu) Co. Ltd. High-density edge connector
TWM576774U (zh) 2018-11-15 2019-04-11 香港商安費諾（東亞）有限公司 具有防位移結構之金屬殼體及其連接器
EP3914232A1 (en) 2019-01-25 2021-12-01 F. Hoffmann-La Roche AG Lipid vesicle for oral drug delivery
CA3130431A1 (en) 2019-02-20 2020-08-27 Roche Innovation Center Copenhagen A/S Phosphonoacetate gapmer oligonucleotides
JP2022521512A (ja) 2019-02-20 2022-04-08 ロシュ イノベーション センター コペンハーゲン エーエス 新規ホスホルアミダイト
TWM582251U (zh) * 2019-04-22 2019-08-11 香港商安費諾（東亞）有限公司 Connector set with built-in locking mechanism and socket connector thereof
BR112021021720A2 (pt) * 2019-04-30 2021-12-28 Univ Pennsylvania Composições úteis para tratamento de doença de pompe
CN110283794B (zh) * 2019-05-30 2021-04-23 伍泽堂 重组溶瘤病毒以及制备方法、应用和药物
BR112021026365A2 (pt) 2019-06-26 2022-05-10 Biorchestra Co Ltd Nanopartículas micelares e usos das mesmas
US10844383B1 (en) 2019-09-18 2020-11-24 Dasman Diabetes Institute Microrna dyslipidemia inhibitor
US11588277B2 (en) 2019-11-06 2023-02-21 Amphenol East Asia Ltd. High-frequency electrical connector with lossy member
US11799230B2 (en) 2019-11-06 2023-10-24 Amphenol East Asia Ltd. High-frequency electrical connector with in interlocking segments
JP2023509845A (ja) 2019-12-13 2023-03-10 インスピルナ，インコーポレーテッド 金属塩及びその使用
US11058710B1 (en) 2020-02-14 2021-07-13 Dasman Diabetes Institute MicroRNA ANGPTL3 inhibitor
EP4114938A1 (en) * 2020-03-04 2023-01-11 The Trustees of Indiana University Methods to re-engage a fetal wound healing pathway for adult skin repair
WO2021207644A1 (en) * 2020-04-09 2021-10-14 Biovista, Inc. Compositions and methods for treating viral infections
US20230174984A1 (en) * 2020-05-11 2023-06-08 The Florey Indtitute of Neuroscience and Mental Health Compositions and methods for treating disorders associated with loss-of-function mutations in syngap1
US11652307B2 (en) 2020-08-20 2023-05-16 Amphenol East Asia Electronic Technology (Shenzhen) Co., Ltd. High speed connector
CN212874843U (zh) 2020-08-31 2021-04-02 安费诺商用电子产品(成都)有限公司 电连接器
EP4352228A2 (en) * 2021-05-18 2024-04-17 Cornell University Use of microrna mimics to inhibit or treat liver disease
WO2023067038A1 (en) 2021-10-22 2023-04-27 Roche Innovation Center Copenhagen A/S Process for oligonucleotide purification
WO2023122805A1 (en) 2021-12-20 2023-06-29 Vestaron Corporation Sorbitol driven selection pressure method
WO2023170659A1 (en) 2022-03-11 2023-09-14 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Breast cancer diagnostic and treatment
US20230399644A1 (en) * 2022-04-29 2023-12-14 University Of Massachusetts Selective rna-modulating agents
CN114990159A (zh) * 2022-05-18 2022-09-02 昆明理工大学 一种micorRNA206抑制HCV增殖的建立方法
WO2024033444A1 (en) * 2022-08-09 2024-02-15 Geg Tech Transient expression system for rna, for cosmetic uses
WO2024033446A1 (en) * 2022-08-09 2024-02-15 Geg Tech Transient expression system for rna, for gene editing
WO2024033448A1 (en) * 2022-08-09 2024-02-15 Geg Tech Transient expression system for rna, for vaccination
WO2024033441A1 (en) * 2022-08-09 2024-02-15 Geg Tech Transient expression system for rna

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2806208A (en) 1951-09-29 1957-09-10 Columbia Broadcasting Syst Inc Vacuum tube voltmeter
US4962029A (en) 1987-10-02 1990-10-09 Cetus Corporation Covalent oligonucleotide-horseradish peroxidase conjugate
US4914210A (en) * 1987-10-02 1990-04-03 Cetus Corporation Oligonucleotide functionalizing reagents
US4920115A (en) * 1988-12-28 1990-04-24 Virginia Commonwealth University Method of lowering LDL cholesterol in blood
WO2002081494A1 (en) 2001-03-26 2002-10-17 Sirna Therapeutics, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
JPH06311885A (ja) 1992-08-25 1994-11-08 Mitsubishi Kasei Corp Ｃ型肝炎ウイルス遺伝子に相補的なアンチセンス化合物
US6433159B1 (en) * 1992-09-10 2002-08-13 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus associated diseases
US6423489B1 (en) 1992-09-10 2002-07-23 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus-associated diseases
EP0662157B1 (en) 1992-09-10 2001-06-20 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis c virus-associated diseases
JPH10503364A (ja) 1994-05-10 1998-03-31 ザ ジェネラル ホスピタル コーポレーション Ｃ型肝炎ウイルスのアンチセンス阻害
US5919795A (en) 1995-06-07 1999-07-06 Pfizer Inc. Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion
AU716151B2 (en) * 1996-11-27 2000-02-17 Pfizer Inc. Apo B-secretion/MTP inhibitory amides
CA2283379A1 (en) * 1997-03-05 1998-09-11 Michael G. Katze Novel screening methods to identify agents that selectively inhibit hepatitis c virus replication
DE04020014T1 (de) 1997-09-12 2006-01-26 Exiqon A/S Bi-zyklische - Nukleosid,Nnukleotid und Oligonukleotid-Analoga
WO1999042275A1 (en) * 1998-02-20 1999-08-26 Decoma International Corp. Mold clamp
ATE465168T1 (de) 1999-03-18 2010-05-15 Exiqon As Xylo-lna analoge
EP1163250B1 (en) 1999-03-24 2006-07-12 Exiqon A/S Improved synthesis of ¬2.2.1|bicyclo nucleosides
NZ514348A (en) * 1999-05-04 2004-05-28 Exiqon As L-ribo-LNA analogues
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
JP2003511016A (ja) 1999-10-04 2003-03-25 エクシコン エ／エス オリゴヌクレオチドを補充する高親和性ｒｎアーゼｈの設計
IL139450A0 (en) 1999-11-10 2001-11-25 Pfizer Prod Inc Methods of administering apo b-secretion/mtp inhibitors
AU2001277170A1 (en) 2000-07-25 2002-02-05 Authentisure, Inc. Unified trust model providing secure identification, authentication and validation of physical products and entities, and processing, storage, and exchange of information
DK1334109T3 (da) 2000-10-04 2006-10-09 Santaris Pharma As Forbedret syntese af purin-blokerede nukleinsyre-analoger
AU2002250236A1 (en) * 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
US20030125241A1 (en) 2001-05-18 2003-07-03 Margit Wissenbach Therapeutic uses of LNA-modified oligonucleotides in infectious diseases
AU2002328792A1 (en) 2001-07-12 2003-01-29 Santaris Pharma A/S Method for preparation of lna phosphoramidites
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
CA2462144C (en) 2001-09-28 2016-09-20 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Micro-rna molecules
US7459461B2 (en) * 2001-10-19 2008-12-02 Ortho-Mcneil Pharmaceutical, Inc. Phosphonic acid compounds as inhibitors of serine proteases
ATE519774T1 (de) 2002-02-20 2011-08-15 Sirna Therapeutics Inc Durch eine störung der rna vermittelte inhibierung der genexpression des hepatitis c virus (hcv) mit kurzer, störender nukleinsäure (short interfering nucleic acid, sina)
ES2290448T3 (es) 2002-05-08 2008-02-16 Santaris Pharma A/S Sistesis de derivados de acidos nucleicos bloqueados.
UA79300C2 (en) * 2002-08-12 2007-06-11 Janssen Pharmaceutica Nv N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
WO2004014852A2 (en) 2002-08-12 2004-02-19 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of hcv replication
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
CA2505801A1 (en) 2002-11-13 2004-05-27 Rosanne Crooke Antisense modulation of apolipoprotein b expression
EP2141233B1 (en) 2002-11-18 2016-10-19 Roche Innovation Center Copenhagen A/S Antisense design
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
FR2848572B1 (fr) 2002-12-12 2005-12-09 Univ Joseph Fourier Molecules inhibitrices de la synthese proteique du virus de l'hepatite c et procede de criblage desdites molecules inhibitrices
WO2004069991A2 (en) 2003-02-10 2004-08-19 Santaris Pharma A/S Oligomeric compounds for the modulation of survivin expression
KR20050115231A (ko) 2003-02-10 2005-12-07 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 포유동물 세포의 조절
WO2005013901A2 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
WO2005013905A2 (en) 2003-08-07 2005-02-17 Avi Biopharma, Inc. SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION
US20050142581A1 (en) 2003-09-04 2005-06-30 Griffey Richard H. Microrna as ligands and target molecules
AU2004294567A1 (en) 2003-11-26 2005-06-16 University Of Massachusetts Sequence-specific inhibition of small RNA function
UA83510C2 (en) 2003-12-09 2008-07-25 Янссен Фармацевтика Н.В. N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b
KR20070006709A (ko) 2003-12-23 2007-01-11 산타리스 팔마 에이/에스 Ｂｃｌ-2의 조절을 위한 올리고머 화합물
EP2295604B1 (en) 2004-02-09 2015-04-08 Thomas Jefferson University Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features
CA2556435C (en) 2004-02-13 2014-08-12 The Rockefeller University Anti-microrna oligonucleotide molecules
US20050182005A1 (en) 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
DE102004015101B4 (de) 2004-03-27 2012-04-26 Eastman Kodak Co. Verfahren und Sensoreinrichtung zum Steuern eines endlosen, eine Naht aufweisenden Transportmediums für eine Druckmaschine
CA2562390C (en) 2004-04-07 2014-12-02 Exiqon A/S Novel methods for quantification of micrornas and small interfering rnas
US7365058B2 (en) 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
BRPI0509979A (pt) 2004-04-20 2007-10-16 Genaco Biomedical Products Inc método para detectar ncrna
CA2564503C (en) 2004-05-04 2015-12-29 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of mir-122 in hepatitis c virus infected subjects and cells
US7579451B2 (en) 2004-07-21 2009-08-25 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a modified or non-natural nucleobase
US20080213891A1 (en) 2004-07-21 2008-09-04 Alnylam Pharmaceuticals, Inc. RNAi Agents Comprising Universal Nucleobases
FR2873694B1 (fr) 2004-07-27 2006-12-08 Merck Sante Soc Par Actions Si Nouveaux aza-indoles inhibiteurs de la mtp et apob
AU2005330637B2 (en) 2004-08-04 2012-09-20 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
WO2006020768A2 (en) 2004-08-10 2006-02-23 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides
CA2576860A1 (en) * 2004-08-10 2006-02-23 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein b expression
WO2006027776A1 (en) 2004-09-07 2006-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
EP2377873B1 (en) 2004-09-24 2014-08-20 Alnylam Pharmaceuticals, Inc. RNAi modulation of ApoB and uses thereof
EP2281888B1 (en) 2004-11-12 2015-01-07 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
AU2005306533B2 (en) 2004-11-17 2012-05-31 Arbutus Biopharma Corporation siRNA silencing of apolipoprotein B
US20060185027A1 (en) 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
EP1959012A3 (en) 2004-12-29 2009-12-30 Exiqon A/S Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAs and their target mRNAs
US20070065840A1 (en) * 2005-03-23 2007-03-22 Irena Naguibneva Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS
BRPI0607555A2 (pt) 2005-04-19 2009-09-15 Surface Logix Inc inibidores da proteìna microssomal de transferência de triglicirideo e secreção de apo-b
US20060265771A1 (en) * 2005-05-17 2006-11-23 Lewis David L Monitoring microrna expression and function
WO2006133022A2 (en) 2005-06-03 2006-12-14 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
CA2618995A1 (en) 2005-08-10 2007-02-22 The Rockefeller University Antagomirs for use in inhibiting mir-122
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
WO2007027894A2 (en) 2005-08-29 2007-03-08 Isis Pharmaceuticals, Inc. Antisense compounds having enhanced anti-microrna activity
ATE494372T1 (de) * 2005-08-29 2011-01-15 Regulus Therapeutics Inc Verfahren für mir-122a-modulation
KR20080068019A (ko) 2005-09-15 2008-07-22 산타리스 팔마 에이/에스 아포지단백질-ｂ100 발현 억제용 ｒｎａ 길항제 화합물
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
EP2388328A1 (en) 2006-01-27 2011-11-23 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
CA3042781C (en) 2006-04-03 2021-10-19 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EA201100813A1 (ru) * 2006-04-03 2012-06-29 Сантарис Фарма А/С Фармацевтическая композиция
JP5731115B2 (ja) 2006-05-05 2015-06-10 アイシス ファーマシューティカルズ， インコーポレーテッド 遺伝子発現を調節するための化合物および方法
WO2007134181A2 (en) 2006-05-11 2007-11-22 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US7694029B2 (en) 2006-08-02 2010-04-06 International Business Machines Corporation Detecting miscabling in a storage area network
US20080199961A1 (en) 2006-08-25 2008-08-21 Avi Biopharma, Inc. ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS
EP2076257A4 (en) 2006-09-15 2014-04-16 Belrose Pharma Inc POLYMER CONJUGATES WITH POSITIVELY LOADED PARTS
JP2010503707A (ja) 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド オリゴヌクレオチドの送達を目的としたヒンダードエステル系生体分解性リンカー
EP2090665A2 (en) 2006-10-20 2009-08-19 Exiqon A/S Novel human microRNAs associated with cancer
WO2008057234A2 (en) 2006-10-24 2008-05-15 The Board Of Trustees Of The Leland Stanford Junior University Modulation of t cell signaling threshold and t cell sensitivity to antigens
CN101554074B (zh) 2006-10-30 2012-08-22 诺基亚公司 为用户设备提供运营商控制的移动性的方法、设备和系统
CA2681568C (en) 2006-11-23 2019-01-08 Querdenker Aps Oligonucleotides for modulating target rna activity
US20090137504A1 (en) 2006-12-21 2009-05-28 Soren Morgenthaler Echwald Microrna target site blocking oligos and uses thereof
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
WO2008124384A2 (en) * 2007-04-03 2008-10-16 Aegerion Pharmaceuticals, Inc. Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c
US8278425B2 (en) 2007-05-30 2012-10-02 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
ES2386492T3 (es) 2007-06-08 2012-08-21 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos carbocíclicos
CN101821390A (zh) 2007-06-14 2010-09-01 米尔克斯治疗有限责任公司 用于调节靶rna活性的寡核苷酸
US20090082297A1 (en) * 2007-06-25 2009-03-26 Lioy Daniel T Compositions and Methods for Regulating Gene Expression
WO2009032083A1 (en) 2007-08-29 2009-03-12 President And Fellows Of Harvard College Methods of increasing gene expression through rna protection
ES2463665T3 (es) 2007-10-04 2014-05-28 Stella Aps Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
US8361980B2 (en) * 2008-03-07 2013-01-29 Santaris Pharma A/S Pharmaceutical compositions for treatment of microRNA related diseases
DK2310505T3 (en) 2008-06-30 2017-10-16 Roche Innovation Ct Copenhagen As ANTIDOT oligomers
ES2541442T3 (es) 2008-08-01 2015-07-20 Roche Innovation Center Copenhagen A/S Modulación mediada por microARN de factores estimulantes de colonias
WO2010013999A1 (en) 2008-08-01 2010-02-04 Twister B.V. Cyclonic separator with a volute outlet duct
EP2421970B1 (en) 2009-04-24 2016-09-07 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
US8942209B2 (en) 2009-08-12 2015-01-27 Qualcomm Incorporated Systems and methods for supporting an enhanced serving cell change when moving among different cell types
WO2011048125A1 (en) 2009-10-20 2011-04-28 Santaris Pharma A/S Oral delivery of therapeutically effective lna oligonucleotides

Similar Documents

Publication Publication Date Title
JP2010539959A5 (ja)
US20220042102A1 (en) Mirna fingerprint in the diagnosis of lung cancer
ES2503741T3 (es) Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
US9284554B2 (en) Micro-RNA scaffolds and non-naturally occurring micro-RNAs
US8748101B2 (en) Methods, compositions, and devices utilizing MicroRNA to determine physiological conditions
CA2681568C (en) Oligonucleotides for modulating target rna activity
EP2341145A1 (en) miRNA fingerprint in the diagnosis of diseases
US20110151430A1 (en) VIRUS-SPECIFIC miRNA SIGNATURES FOR DIAGNOSIS AND THERAPEUTIC TREATMENT OF VIRAL INFECTION
EP2354246A1 (en) miRNA in the diagnosis of ovarian cancer
JP2011516033A5 (ja) 急性骨髄性白血病（ａｍｌ）における細胞遺伝学および予後と関連するマイクロｒｎａシグネチャーおよびその使用
US8859239B2 (en) Methods for small RNA sequencing
Efimenko et al. Data supporting that miR-92a suppresses angiogenic activity of adipose-derived mesenchymal stromal cells by down-regulating hepatocyte growth factor
NM_205822 et al. Supplementary Table
Ruan et al. Supplement for article entitled “HuMiTar: A sequence-based method for prediction of human microRNA targets”
Omnibus AUC: area under curve. KEGG: Kyoto Encyclopedia of Genes and Genomes. GEO: Gene
Name_ID SUPPLEMENTARY TABLE
EP3862442A2 (en) Method for the early diagnosis of cancer by means of ddpcr analysis of mirna in liquid biopsy
Bandyopadhyay et al. Supplementary materials for TargetMiner: MicroRNA target pre-diction with systematic identification of tissue specific negative examples
SÜSLÜER et al. Research Article Detection of miRNA Expression Alteration in Diffuse and High Grade Glial Tumors